The impact of carbapenemases on antimicrobial development and therapy.
about
Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysisCarbapenemases: the versatile beta-lactamasesInhibition of Class A β-Lactamases by Carbapenems: Crystallographic Observation of Two Conformations of Meropenem in SHV-1Metallo-beta-lactamases: the quiet before the storm?Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 beta-lactamase in koreaDissemination of multidrug resistant Acinetobacter baumannii in various hospitals of Antananarivo MadagascarOutbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia.Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from KoreaAn investigation of drug-resistant Acinetobacter baumannii infections in a comprehensive hospital of East China.Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolatesOutbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil.Clonal spread of imipenem-resistant Acinetobacter baumannii among different cities of China.In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in ItalyDoripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.The First Outbreak Caused by Acinetobacter baumannii ST208 and ST195 in China.The role of carbapenems in initial therapy for serious Gram-negative infections.Use of Comparative Genomics To Characterize the Diversity of Acinetobacter baumannii Surveillance Isolates in a Health Care Institution.Observations on carbapenem resistance by minimum inhibitory concentration in nosocomial isolates of Acinetobacter species: an experience at a tertiary care hospital in North India.The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii.In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp.An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.Increasing prevalence and diversity of metallo-beta-lactamases in Pseudomonas spp., Acinetobacter spp., and Enterobacteriaceae from Korea.First report of the carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter baumannii isolates in ItalyOutbreaks in distinct regions due to a single Klebsiella pneumoniae clone carrying a bla VIM-1 metallo-{beta}-lactamase gene.Imipenem-resistant Acinetobacter baumannii carrying the ISAba1-bla OXA-23,51 and ISAba1-bla ADC-7 genes in Monteria, Colombia
P2860
Q24674712-7434978A-1976-4901-90BC-3A560A98E826Q24685034-DFFBFDB4-9FE2-46B8-B9E1-F4B35CEB0B69Q27651899-51F11A43-5E44-408F-BFEB-71A869B44148Q33755227-C09BA9D4-D5AA-40C9-B622-2774602B49A5Q33859045-EA0A3ABE-801F-4A51-9531-F2229391A3DEQ34020061-0C70EE14-11F5-45A2-AA7D-B7BFF03FAAF7Q34042432-31E52189-1DB0-4247-9C64-5F75FE86F9CAQ34123619-92F41FBE-F219-473E-AF60-1938FAC30217Q35084121-21CEB3F0-889B-476B-9CD8-7130EC4E8F30Q35139440-B84AF44E-AC74-438A-80E9-D2F8904FA9C9Q35155708-69EB6EE4-330F-4B07-AB19-9604CD717040Q36314596-AD403E28-3C0D-4DC9-A85A-FCF1944B315DQ36509591-C7A08FBA-D76F-408F-A2C8-ADC777D6D1DAQ36670323-FA8F1ABD-C211-4733-89B1-DE8DF61CF0D9Q36828244-84B4FBED-5ABE-4595-ACDF-1852D86455BBQ37169849-18CF5550-7C97-4797-A762-195E8B041ED3Q37287931-B047D7EC-22F2-4AD2-8ED9-0334F9F600EBQ37339564-AD1138B6-F1AC-4B7F-8460-71FEB481891FQ37624613-D756F6C4-93A0-46D7-9715-74FADE155B21Q40049619-991C83E1-9B24-4706-80A6-A8600B411DDBQ40289810-16C0CE4C-14D0-41EE-85E7-2F115D27530AQ41781795-2BF766CC-6AB8-4634-BA85-4AB9B9AE2ADAQ42112448-0B8B8495-7ADA-43C3-9874-F988D188B7A2Q42408826-91BB05EB-0266-4450-8259-63A332D5212CQ42561356-FC800F2B-0964-4318-B37F-CD648FFE5B9CQ42594626-CF0C3D33-1C24-4CE9-A85A-0C4031150806
P2860
The impact of carbapenemases on antimicrobial development and therapy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The impact of carbapenemases on antimicrobial development and therapy.
@ast
The impact of carbapenemases on antimicrobial development and therapy.
@en
The impact of carbapenemases on antimicrobial development and therapy.
@nl
type
label
The impact of carbapenemases on antimicrobial development and therapy.
@ast
The impact of carbapenemases on antimicrobial development and therapy.
@en
The impact of carbapenemases on antimicrobial development and therapy.
@nl
prefLabel
The impact of carbapenemases on antimicrobial development and therapy.
@ast
The impact of carbapenemases on antimicrobial development and therapy.
@en
The impact of carbapenemases on antimicrobial development and therapy.
@nl
P1476
The impact of carbapenemases on antimicrobial development and therapy.
@en
P2093
David M Livermore
P304
P577
2002-02-01T00:00:00Z